Promising new data on lutetium-177 PSMA radioligand therapy

According to a presentation given last week in San Francisco, lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radioligand therapy has significant clinical activity in men with metastatic prostate cancer (as opposed to just in men with very late stages of prostate cancer). … READ MORE …

Yet another new PMSA-linked radioisotope enters clinical trials in prostate cancer

As many readers will be aware, there has been a lot of ongoing research using the gallium-68 (68Ga) radioisotope linked to various forms of prostate-specific membrane antigen (PSMA) in concert with PET scan imaging to identify sites of early recurrence of prostate cancer. … READ MORE …